NY-AQARA
19.10.2021 15:02:06 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, announced the launch of its Professional Partners Program for smart home installers and integrators. Utilizing Aqara’s decade-long experience in the smart home industry and its comprehensive suite of smart home products, advanced technologies, solutions, and tools, the Professional Partners Program aims to support professional installers in enhancing their service offerings and growing their businesses. The Program also welcomes the broader professional community, such as shading control installers, smart lock locksmiths, home theater installers, interior designers and electricians, to join the Aqara partner network.
With years of experience in offering high-quality products to global consumers, Aqara now seeks to join forces with the professional community to boost adoption of the smart home technology worldwide. As part of Aqara Partners Program, participants will enjoy:
- Priority access to new Aqara products
- Special promotional pricing on certain products
- Comprehensive product training support and resources
- Opportunity to connect with interested Aqara users in local areas
- Marketing support
Starting in October 2021, Aqara has launched an exclusive Smart Roller Shade Controller Package as the first promotional event within the Professional Partners Program for a limited time. The Smart Roller Shade Controller is the global version of Aqara’s most popular roller shade motor, which is designed to automate a variety of roller blinds and even projector screens. Bound with an Aqara hub, the controller allows roller shades to be controlled by mobiles, voice commands (Apple Siri, Google Assistant, Yandex Alice, Naver Clova, etc.), pre-set schedules, and via home automations in which roller shades could be triggered by illumination condition, human motion, room temperature, etc.
To learn more about the Professional Partners Program or register for the Smart Roller Shade Controller Package, please visit our website .
About Aqara
Founded in 2016, Aqara is a leading smart home provider with offices in New York and Shenzhen. The Company provides comprehensive smart home products and solutions that are beautifully designed, long-lasting, and easy to use. Products range from a variety of smart sensors to switches, curtain controllers, and smart door locks. Over the last few years, Aqara has opened more than 600 Aqara stores to provide more personalized smart home solutions for individual households and businesses.
Aqara currently serves more than 2 million customers worldwide, with distribution partners in the United States, EU, Russia, Southeast Asia, Korea, and China. The Company also offers one of the most comprehensive suite of HomeKit compatible smart home solutions in the market, and its products can also be found in Apple Stores across Europe and Asia. As the Company continues to expand its global footprint, Aqara hopes to bring more accessible, smart home technology to households around the world.
For more information, please visit our website and follow our social platforms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005028/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom